ReviewFrontiers in neurology2017
Rethinking Neuroprotection in Severe Traumatic Brain Injury: Toward Bedside Neuroprotection.
Review in Frontiers in neurology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it, 45 citations in OpenAlex.
- Efficacy and safety of erythropoietin for traumatic brain injury.BMC neurology · 2020Pooled it
- Effect of riluzole on cognitive and functional outcomes after severe traumatic brain injury: a randomized controlled trial.BMC neurology · 2026Trial
- Mesenchymal Stromal Cell Implants for Chronic Motor Deficits After Traumatic Brain Injury: Post Hoc Analysis of a Randomized Trial.Neurology · 2024Trial
- Sequential release ofMaterials today. Bio · 2026Article
- A novel peptide inhibitor of TRPM2 channels improves recovery of memory function following traumatic brain injury.Frontiers in synaptic neuroscience · 2025Article
- Relationship Between Location of Cell Transplantation and Recovery for Intracerebral Stem Cell Transplantation for Chronic Traumatic Brain Injury:Neurotrauma reports · 2025Article
- Bioactive hydrogel synergizes neuroprotection, macrophage polarization, and angiogenesis to improve repair of traumatic brain injury.Materials today. Bio · 2024Article
- Review
- Mastering the brain in critical conditions: an update.Intensive care medicine experimental · 2024Article
- Injury-Transplantation Interval-Dependent Amelioration of Axonal Degeneration and Motor Deficit in Rats with Penetrating Traumatic Brain Injury.Neurotrauma reports · 2023Article
- Xenon treatment after severe traumatic brain injury improves locomotor outcome, reduces acute neuronal loss and enhances early beneficial neuroinflammation: a randomized, blinded, controlled animal study.Critical care (London, England) · 2020Article
- Extracellular Vesicles Mediate Neuroprotection and Functional Recovery after Traumatic Brain Injury.Journal of neurotrauma · 2020Article
- Resilience to Injury: A New Approach to Neuroprotection?Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2020Review
- Resuscitation Strategies for Traumatic Brain Injury.Current surgery reports · 2019Article
- Xenon improves long-term cognitive function, reduces neuronal loss and chronic neuroinflammation, and improves survival after traumatic brain injury in mice.British journal of anaesthesia · 2019Article
- A Patient-Independent Significance Test by Means of False-Positive Rates in Selected Correlation Analysis of Brain Multimodal Monitoring Data.Computational and mathematical methods in medicine · 2018Article
- Enduring Neuroprotective Effect of Subacute Neural Stem Cell Transplantation After Penetrating TBI.Frontiers in neurology · 2018Review
- Neuroprotection in Traumatic Brain Injury: Mesenchymal Stromal Cells can Potentially Overcome Some Limitations of Previous Clinical Trials.Frontiers in neurology · 2018Review
- Virtual Reality for Traumatic Brain Injury.Frontiers in neurology · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Neuroprotection after traumatic brain injury (TBI) is an important goal pursued strenuously in the last 30 years. The acute cerebral injury triggers a cascade of biochemical events that may worsen the integrity, function, and connectivity of the brain cells and decrease the chance of functional recovery. A number of molecules acting against this deleterious cascade have been tested in the experimental setting, often with preliminary encouraging results. Unfortunately, clinical trials using those candidate neuroprotectants molecules have consistently produced disappointing results, highlighting the necessity of improving the research standards. Despite repeated failures in pharmacological neuroprotection, TBI treatment in neurointensive care units has achieved outcome improvement. It is likely that intensive treatment has contributed to this progress offering a different kind of neuroprotection, based on a careful prevention and limitations of intracranial and systemic threats. The natural course of acute brain damage, in fact, is often complicated by additional adverse events, like the development of intracranial hypertension, brain hypoxia, or hypoperfusion. All these events may lead to additional brain damage and worsen outcome. An approach designed for early identification and prompt correction of insults may, therefore, limit brain damage and improve results.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.